ES2334286T3 - Homoserinlactonas n-aciladas sustituidas. - Google Patents

Homoserinlactonas n-aciladas sustituidas. Download PDF

Info

Publication number: ES2334286T3
Authority: ES; Spain
Prior art keywords: aza; homoserinlactone; group; compound according; compound
Prior art date: 2006-05-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES07733705T

Other languages

English (en)

Spanish (es)

Inventor

David Idris Pritchard

Siri Ram Chhabra

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SECR DEFENCE

UK Secretary of State for Defence

Original Assignee

SECR DEFENCE

UK Secretary of State for Defence

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-22

Filing date

2007-05-22

Publication date

2010-03-08

2007-05-22 Application filed by SECR DEFENCE, UK Secretary of State for Defence filed Critical SECR DEFENCE

2010-03-08 Application granted granted Critical

2010-03-08 Publication of ES2334286T3 publication Critical patent/ES2334286T3/es

Status Active legal-status Critical Current

2027-05-22 Anticipated expiration legal-status Critical

Links

150000001875 compounds Chemical class 0.000 claims abstract description 54
125000000217 alkyl group Chemical group 0.000 claims abstract description 9
125000004432 carbon atom Chemical group C* 0.000 claims abstract description 8
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 8
229910052731 fluorine Inorganic materials 0.000 claims abstract description 7
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 5
229920006395 saturated elastomer Polymers 0.000 claims abstract description 5
-1 n-octyl group Chemical group 0.000 claims description 21
239000002253 acid Substances 0.000 claims description 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
238000000034 method Methods 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
239000000969 carrier Substances 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
125000001931 aliphatic group Chemical group 0.000 abstract description 3
125000001183 hydrocarbyl group Chemical group 0.000 abstract description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
239000000243 solution Substances 0.000 description 18
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
PHSRRHGYXQCRPU-AWEZNQCLSA-N N-(3-oxododecanoyl)-L-homoserine lactone Chemical compound CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O PHSRRHGYXQCRPU-AWEZNQCLSA-N 0.000 description 11
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
230000000694 effects Effects 0.000 description 10
230000035755 proliferation Effects 0.000 description 10
238000002390 rotary evaporation Methods 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000000203 mixture Substances 0.000 description 8
208000023275 Autoimmune disease Diseases 0.000 description 7
239000007787 solid Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
210000004988 splenocyte Anatomy 0.000 description 7
108010062580 Concanavalin A Proteins 0.000 description 6
241001529936 Murinae Species 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
230000029918 bioluminescence Effects 0.000 description 5
238000005415 bioluminescence Methods 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 5
230000001939 inductive effect Effects 0.000 description 5
229910052943 magnesium sulfate Inorganic materials 0.000 description 5
235000019341 magnesium sulphate Nutrition 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
NQTSGLRHWDVARY-UHFFFAOYSA-N 2-fluoro-3-(octylamino)-3-oxopropanoic acid Chemical compound CCCCCCCCNC(=O)C(F)C(O)=O NQTSGLRHWDVARY-UHFFFAOYSA-N 0.000 description 3
HBVNXRIQVTWNJQ-UHFFFAOYSA-N 3-(octylamino)-3-oxopropanoic acid Chemical compound CCCCCCCCNC(=O)CC(O)=O HBVNXRIQVTWNJQ-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000010790 dilution Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
239000011737 fluorine Substances 0.000 description 3
244000005700 microbiome Species 0.000 description 3
239000003226 mitogen Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 3
239000011734 sodium Substances 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
229930105110 Cyclosporin A Natural products 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000012267 brine Substances 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
IDPFEQBTMBKHIE-UHFFFAOYSA-N 3-[methyl(octyl)amino]-3-oxopropanoic acid Chemical compound CCCCCCCCN(C)C(=O)CC(O)=O IDPFEQBTMBKHIE-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
239000006137 Luria-Bertani broth Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
208000035977 Rare disease Diseases 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
150000007513 acids Chemical group 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000003092 anti-cytokine Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000001514 detection method Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000001904 diabetogenic effect Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
UKFXDFUAPNAMPJ-UHFFFAOYSA-N ethylmalonic acid Chemical compound CCC(C(O)=O)C(O)=O UKFXDFUAPNAMPJ-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
101150094443 lasR gene Proteins 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
SEGJNMCIMOLEDM-UHFFFAOYSA-N n-methyloctan-1-amine Chemical compound CCCCCCCCNC SEGJNMCIMOLEDM-UHFFFAOYSA-N 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
210000003024 peritoneal macrophage Anatomy 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
229910000343 potassium bisulfate Inorganic materials 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
150000003385 sodium Chemical class 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

ES07733705T 2006-05-22 2007-05-22 Homoserinlactonas n-aciladas sustituidas. Active ES2334286T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0610042.4A GB0610042D0 (en)	2006-05-22	2006-05-22	Substituted n-acyl homoserine lactones
GB0610042		2006-05-22

Publications (1)

Publication Number	Publication Date
ES2334286T3 true ES2334286T3 (es)	2010-03-08

Family

ID=36660536

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES07733705T Active ES2334286T3 (es)	2006-05-22	2007-05-22	Homoserinlactonas n-aciladas sustituidas.

Country Status (10)

Country	Link
US (1)	US8049020B2 (de)
EP (1)	EP2044046B1 (de)
JP (1)	JP2009537625A (de)
CN (1)	CN101506186A (de)
AT (1)	ATE446290T1 (de)
AU (1)	AU2007252999A1 (de)
DE (1)	DE602007002920D1 (de)
ES (1)	ES2334286T3 (de)
GB (2)	GB0610042D0 (de)
WO (1)	WO2007135466A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102757437B (zh) *	2012-06-12	2014-10-15	中国科学院化学研究所	酞菁纳米棒阵列薄膜及其制备方法与应用
CN103980233B (zh) *	2013-02-08	2017-07-04	中国人民解放军军事医学科学院毒物药物研究所	一种高丝氨酸内酯类衍生物、其制备方法和用途
EP2976076B1 (de)	2013-03-19	2020-03-04	The Scripps Research Institute	Modulatoren von trail zur selektiven tötung von krebszellen
CN104529802A (zh) *	2014-12-13	2015-04-22	西安近代化学研究所	一种合成n,n′-双取代氟代丙二酰胺化合物的方法
CN104496737B (zh) *	2014-12-13	2017-12-22	西安近代化学研究所	一种合成α‑胺甲酰基氟乙酸酯化合物的方法
US10195177B2 (en)	2015-10-01	2019-02-05	The University Of Toledo	Use of acyl-homoserine lactone derivatives as anti-thrombotic agents
CN110003148B (zh) *	2019-04-29	2023-03-24	安徽安力肽生物科技有限公司	一种高丝氨酸内酯盐酸盐的制备方法
CN116940549B (zh)	2021-03-09	2026-02-03	巴斯夫欧洲公司	丙二酰胺类及其作为除草剂的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2904556A (en) *	1958-08-06	1959-09-15	Dow Chemical Co	Phthalides
GB9108307D0 (en) *	1991-04-18	1991-06-05	Univ Nottingham	Autoinducer
ES2139079T3 (es) *	1993-07-02	2000-02-01	Univ Nottingham	Compuestos inmunosupresores y antialergicos, tales como n-(3-oxohexanoil)-homoserina-lactona.
US6337347B1 (en) *	1998-06-18	2002-01-08	The Research & Development Institute, Inc.	Autoinducer compounds
GB0007588D0 (en) *	2000-03-30	2000-05-17	Univ Nottingham	N-Acyl homoserine lactones

2006
- 2006-05-22 GB GBGB0610042.4A patent/GB0610042D0/en not_active Ceased
2007
- 2007-05-22 JP JP2009511587A patent/JP2009537625A/ja not_active Ceased
- 2007-05-22 WO PCT/GB2007/050284 patent/WO2007135466A2/en not_active Ceased
- 2007-05-22 DE DE602007002920T patent/DE602007002920D1/de active Active
- 2007-05-22 AU AU2007252999A patent/AU2007252999A1/en not_active Abandoned
- 2007-05-22 US US12/302,258 patent/US8049020B2/en not_active Expired - Fee Related
- 2007-05-22 CN CNA2007800279728A patent/CN101506186A/zh active Pending
- 2007-05-22 EP EP07733705A patent/EP2044046B1/de not_active Not-in-force
- 2007-05-22 AT AT07733705T patent/ATE446290T1/de not_active IP Right Cessation
- 2007-05-22 ES ES07733705T patent/ES2334286T3/es active Active
2008
- 2008-12-03 GB GB0822066A patent/GB2452436A/en not_active Withdrawn

Also Published As

Publication number	Publication date
ATE446290T1 (de)	2009-11-15
DE602007002920D1 (de)	2009-12-03
WO2007135466A3 (en)	2008-01-10
GB2452436A (en)	2009-03-04
US8049020B2 (en)	2011-11-01
US20100286261A1 (en)	2010-11-11
AU2007252999A1 (en)	2007-11-29
GB0822066D0 (en)	2009-01-07
EP2044046A2 (de)	2009-04-08
JP2009537625A (ja)	2009-10-29
WO2007135466A2 (en)	2007-11-29
GB0610042D0 (en)	2006-06-28
CN101506186A (zh)	2009-08-12
EP2044046B1 (de)	2009-10-21

Publication	Publication Date	Title
ES2334286T3 (es)	2010-03-08	Homoserinlactonas n-aciladas sustituidas.
ES2940611T3 (es)	2023-05-09	Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
KR101605151B1 (ko)	2016-03-21	화학요법에 의해 유도되는 통증의 예방 또는 치료를 위한 시그마 리간드
KR20220123381A (ko)	2022-09-06	하전된 이온 채널 차단제 및 사용 방법
KR102588426B1 (ko)	2023-10-13	치환 디히드로피롤로피라졸 유도체
US11332446B2 (en)	2022-05-17	Charged ion channel blockers and methods for use
EP4054336A1 (de)	2022-09-14	Phosphonium-ionenkanalblocker und verfahren zur verwendung
CN102105436A (zh)	2011-06-22	被赋予高适口性的口服脂肪酸衍生物
ES2856204T3 (es)	2021-09-27	Compuestos de ciclohexenilo, composiciones que los comprenden y usos de los mismos
AU2012340519A1 (en)	2014-06-05	Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)
JP5719764B2 (ja)	2015-05-20	大環状化合物および治療方法
WO2019079759A1 (en)	2019-04-25	ANTI-PERSISTENCE AND ANTI-VIRULENCE COMPOUNDS WITH BROAD SPECTRUM
WO2013070118A1 (ru)	2013-05-16	(зк,4к,58)-4-ациламино-5-амино-3-(1-этил-пропокси)-циклогекс-1- ен-карбоновые кислоты, их эфиры и способ применения
AU2019399772B2 (en)	2021-11-04	A compound for treating osteoarthritis
JP6195100B2 (ja)	2017-09-13	プロテインキナーゼｇに対する高阻害活性を有する化合物及びその製造方法
ES3037130T3 (en)	2025-09-29	Anti-inflammatory carboxamide derivatives
NIŢULESCU et al.	2010	Synthesis and pharmacological evaluation of some new pyrazole derivatives
RU2501795C1 (ru)	2013-12-20	N-R-АМИДЫ (Z)-2[(3-ЭТОКСИКАРБОНИЛ)-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-ФЕНИЛ-4-ОКСОБУТ-2-ЕНОВЫХ КИСЛОТ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ
US11149062B2 (en)	2021-10-19	HDAC inhibitors and methods of treatment using the same
JP2006232707A (ja)	2006-09-07	癌転移抑制剤
US20260125388A1 (en)	2026-05-07	Gaba(a) receptor modulators and methods to control smooth muscle contraction and inflammation
WO2024077061A2 (en)	2024-04-11	Gaba(a) receptor modulators and methods to control smooth muscle contraction and inflammation
AU2024352930A1 (en)	2026-02-05	Substituted derivatives of isoindoles for use in the treatment of central nervous system disorders
RU2657559C2 (ru)	2018-06-14	Медицинское применение фармацевтических композиций на основе роданиновых производных бензотиофена, ингибиторов белка клеточного деления FtsZ
CN119823089A (zh)	2025-04-15	一种n-苯基-2-氮杂环乙酰胺衍生物及其制备方法与应用